Jazz Pharmaceuticals JAZZ Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | |||||
| Defitelio/defibrotide | $199.43M-7.9% | $216.57M+17.7% | $184M-5.3% | $194.29M-1.8% | |
| Epidiolex/Epidyolex | $1.06B+8.9% | $972.42M+15.0% | $845.47M+14.8% | $736.4M+58.8% | |
| High-sodium oxybate AG royalty revenue | $211.68M-2.7% | $217.58M+187% | $75.92M— | $0— | |
| Modeyso | $48.04M— | —— | $0— | —— | |
| Other | $20.16M+75.7% | $11.47M-17.2% | $13.85M+108% | $6.64M-32.2% | |
| Rylaze/Enrylaze | $402.89M-1.9% | $410.85M+4.2% | $394.23M+40.0% | $281.66M— | |
| Vyxeos | $146.67M-9.8% | $162.6M+10.2% | $147.5M+15.2% | $127.98M-4.5% | |
| Xyrem | $145.99M-37.6% | $233.82M-59.0% | $569.73M-44.2% | $1.02B-19.4% | |
| Xywav | $1.66B+12.5% | $1.47B+15.7% | $1.27B+32.8% | $958.43M+79.0% | |
| Zepzelca | $307.28M-4.1% | $320.32M+10.6% | $289.53M+7.3% | $269.91M+9.4% | |
| Ziihera | $24.84M+2,263% | $1.05M— | $0— | $0— | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | |||||
| All other | $94.88M-1.3% | $96.14M+28.2% | $74.98M+51.9% | $49.36M+14.4% | |
| Europe | $341.68M+9.3% | $312.72M+16.1% | $269.24M+12.4% | $239.64M+3.8% | |
| U.S. | $3.83B+4.7% | $3.66B+4.9% | $3.49B+3.5% | $3.37B+19.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Jazz Pharmaceuticals break its business down?
- Jazz Pharmaceuticals (JAZZ) reports revenue from contract with customer, excluding assessed tax by product across 12 parts — Defitelio/defibrotide, Epidiolex/Epidyolex, High-sodium oxybate AG royalty revenue, Modeyso and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Jazz Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Jazz Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
